ChromaDex (NASDAQ:CDXC) Now Covered by StockNews.com

StockNews.com began coverage on shares of ChromaDex (NASDAQ:CDXC) in a research note released on Tuesday morning. The brokerage issued a buy rating on the stock.

A number of other brokerages have also recently weighed in on CDXC. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of ChromaDex in a report on Monday, March 17th. LADENBURG THALM/SH SH raised their price objective on ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a report on Wednesday, March 5th.

ChromaDex Stock Performance

The firm has a fifty day simple moving average of $6.16 and a 200-day simple moving average of $5.44. ChromaDex has a 1-year low of $2.31 and a 1-year high of $9.18. The stock has a market cap of $611.50 million, a PE ratio of 787.29 and a beta of 2.21.

Hedge Funds Weigh In On ChromaDex

A number of large investors have recently modified their holdings of CDXC. USA Financial Formulas bought a new position in ChromaDex during the 4th quarter worth approximately $25,000. State of Wyoming bought a new position in ChromaDex during the 4th quarter worth approximately $39,000. Mercer Global Advisors Inc. ADV bought a new position in ChromaDex during the 4th quarter worth approximately $53,000. Truist Financial Corp bought a new position in ChromaDex during the 4th quarter worth approximately $54,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in ChromaDex during the 4th quarter worth approximately $67,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.